CJC 1295 with dac (synonym CJC1295/DAC, modified form (GRF 1-29) with drug affinity complex) belongs to class of tetrasubtituted peptide hormones and contains 30 amino acids; also it can be described as analog of GH releasing hormone. Its molecular formula is C165H269N47O46 and its molecular mass is 3647.28. CJC 1295 with DAC-complex was the first time developed and produced by Canadian scientists with initial purpose to find way to increase effective half-life period of growth hormone release hormone. The very first clinical studies regarding this research compound took place in the year of 2000. In 2006 a study concerning efficacy and effectiveness as well as safety profile of CJC 1295/DAC was done, it includes two double-blind, randomized, placebo-controlled trials. Due to having DAC-complex this research compound possesses greater binding affinity towards GHRH receptors, which in turn protects that hormone from degradation. CJC1295 w/t dac-complex also stimulates production of hormone of growth and IGF-1 without increasing of prolactin, and that leads to effective fat loss. The same time it has ability to promote synthesis of proteins and therefore increasing growth of muscle tissues. PEPTIDE WARNING: This product is a lyophilized peptide for research use only. This product is NOT for human use and can be harmful if ingested. This product is for research/laboratory use only. This product is NOT in a sterile solution and is NOT to be injected. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and should not be misbranded, misused or mislabeled as a drug, food or cosmetic.